Evotec (NASDAQ:EVO) Sees Strong Trading Volume – Still a Buy?

Evotec AG (NASDAQ:EVO) saw strong trading volume on Monday . 102,048 shares were traded during mid-day trading, a decline of 26% from the previous session’s volume of 137,851 shares.The stock last traded at $2.3550 and had previously closed at $2.42.

Analyst Upgrades and Downgrades

A number of brokerages have commented on EVO. Berenberg Bank initiated coverage on Evotec in a research report on Tuesday, February 3rd. They set a “buy” rating for the company. Wall Street Zen upgraded Evotec from a “sell” rating to a “hold” rating in a report on Saturday, January 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Evotec in a research report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $7.00.

Evotec Stock Performance

The firm’s fifty day moving average price is $3.19 and its 200 day moving average price is $3.37. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.03 and a current ratio of 2.12.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of EVO. Pitcairn Co. purchased a new stake in shares of Evotec during the 2nd quarter worth about $1,097,000. HRT Financial LP bought a new stake in shares of Evotec in the 4th quarter valued at approximately $72,000. XTX Topco Ltd bought a new stake in shares of Evotec in the 2nd quarter valued at approximately $66,000. Bank of America Corp DE increased its holdings in Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after buying an additional 9,289 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in Evotec by 62.2% in the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock worth $50,000 after buying an additional 4,600 shares during the last quarter. Hedge funds and other institutional investors own 5.81% of the company’s stock.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.